How the Mounjaro Jab Actually Works (and What Gets It Wrong)

The biggest misconception: Mounjaro is not just a stronger version of existing jabs

A common assumption is that Mounjaro works in the same way as semaglutide-based injections, just at a higher intensity. That is not accurate. Semaglutide activates one receptor, GLP-1. Tirzepatide, the active ingredient in the Mounjaro jab, activates two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). These are distinct hormonal pathways, and engaging both produces effects that neither pathway achieves alone.

GLP-1 receptor activation is what most people have read about: it slows gastric emptying, which means food stays in the stomach longer and hunger signals take longer to return. It also acts on areas of the brain involved in appetite regulation, and if you want to understand how Mounjaro works across both of these hormonal pathways in more detail, that page walks through the full mechanism clearly. You can read more about that specific angle on how Mounjaro acts on the brain.

The GIP pathway is less discussed but matters significantly. GIP receptors are found in fat tissue and in the brain's appetite centres. Activating them appears to improve how the body processes and stores dietary fat, and to add an independent suppressive effect on appetite on top of what GLP-1 contributes. The result is a combined signal that is meaningfully stronger than either hormone produces alone. This is why tirzepatide is described as a dual agonist rather than simply a next-generation GLP-1 drug, the mechanism is genuinely different. If you want a closer look at what this means at the cellular level, the page on how tirzepatide works in the body goes into more detail.

What the jab itself does once it is injected

Mounjaro is delivered as a once-weekly subcutaneous injection (under the skin, not into a vein or muscle) using a pre-filled KwikPen. The pen contains four weekly doses. Common injection sites are the abdomen, thigh, or upper arm; rotating between them helps avoid irritation at any single spot.

After injection, tirzepatide is absorbed slowly from the tissue and acts over the following seven days. The extended activity is why it is given weekly rather than daily. Appetite suppression tends to be most noticeable in the first few days after each injection, gradually easing toward the end of the week before the next dose.

The pen itself arrives in plain, unbranded packaging via DPD with tracking sent to your phone, so there is no guessing when it will land. It needs to be refrigerated at 2–8°C; the Patient Information Leaflet that comes with every pen gives the exact guidance on how long a pen can be kept at room temperature if needed, always follow that, not general advice online.

For a broader overview of what the treatment involves from the first week onward, the Mounjaro jab page covers the practical side of starting treatment.

How the dose progression fits the mechanism

Treatment always starts at 2.5 mg. That first pen's job is adjustment, not weight loss, it gives your body time to adapt to the receptor activation without triggering the nausea and gastrointestinal discomfort that a full therapeutic dose would cause from day one. This is not a quirk of the medicine; it reflects how potent the dual-agonist effect is when your system first encounters it.

From 2.5 mg, the prescriber titrates upward, typically in four-week steps, through 5, 7.5, 10, 12.5, and up to 15 mg. The higher doses are where the strongest appetite suppression and the greatest average weight loss in clinical trials were observed. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants on 15 mg lost around 20–21% of body weight on average over 72 weeks, a result NICE cited in recommending tirzepatide for NHS use. Not everyone reaches the highest dose; the right endpoint is the one your prescriber determines based on your response and tolerance.

The titration schedule is set by your prescriber. Do not adjust your dose timing or skip steps based on anything other than their instruction and the leaflet in the pack. If you have questions about a specific dose, the tirzepatide overview gives licensed strength information, and the FAQs address common questions about the titration process.

Eligibility, the prescription requirement, and where to start

Because Mounjaro is a prescription-only medicine, the mechanism of the jab is only half the picture. The other half is clinical suitability. Under its UK licence, tirzepatide is approved for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

NICE also recommends tirzepatide for NHS use in adults with a BMI of 35 or above and at least one weight-related condition, with the ethnic-background adjustment factored in, details of the phased NHS rollout are summarised on the Mounjaro overview page. Private prescribing through a regulated pharmacy follows the licensed criteria rather than the NHS thresholds, though a prescriber still assesses every case individually.

The NHS page on tirzepatide provides straightforward, patient-facing information on how it works and what to expect. Understanding the mechanism is a reasonable first step; working out whether it is right for you is the conversation that follows. If you are ready for that conversation, check your eligibility with our prescribers, the consultation is free, reviewed the same day by a real clinician, and carries no obligation.